stock
Takeda Pharmaceutical Co Ltd ADR
NYSE | TAK
15
USD
+0.00
(+0.00%
)AT CLOSE (AS OF Aug 15, 2025)
$47B
MARKET CAP
51.72
P/E Ratio
0.29
EPS
$16
52 Week High
$13
52 Week Low
LIFE SCIENCES
Sector
TAK Chart
Recent Chart
Price Action
1D
Candles
Trade Smarter
Automate your trading workflow with powerful tools — built for serious traders.
TAK Technicals
TAK Earnings
Yearly Income Statement (As of Mar 31, 2025)
| Field | Value (JPY) |
|---|---|
| Gross Profit | $3T |
| Total Revenue | $4.6T |
| Cost Of Revenue | $1.6T |
| Costof Goods And Services Sold | $1.6T |
| Operating Income | $343B |
| Selling General And Administrative | $1.1T |
| Research And Development | $730B |
| Operating Expenses | $2.7T |
| Investment Income Net | - |
| Net Interest Income | -$161B |
| Interest Income | $182B |
| Interest Expense | $137B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $761B |
| Income Before Tax | $175B |
| Income Tax Expense | $67B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $108B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $449B |
| Ebitda | $1.2T |
| Net Income | $108B |
Revenue & Profitability
Earnings Performance
TAK Financials
yearly Balance Sheet (As of Mar 31, 2025)
| Field | Value (JPY) |
|---|---|
| Total Assets | $14T |
| Total Current Assets | $2.5T |
| Cash And Cash Equivalents At Carrying Value | $385B |
| Cash And Short Term Investments | $385B |
| Inventory | $1.2T |
| Current Net Receivables | $709B |
| Total Non Current Assets | $12T |
| Property Plant Equipment | $2T |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $3.6T |
| Intangible Assets Excluding Goodwill | $3.6T |
| Goodwill | $5.3T |
| Investments | - |
| Long Term Investments | $362B |
| Short Term Investments | $20B |
| Other Current Assets | $209B |
| Other Non Current Assets | - |
| Total Liabilities | $7.3T |
| Total Current Liabilities | $2.5T |
| Current Accounts Payable | $476B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $549B |
| Total Non Current Liabilities | $4.8T |
| Capital Lease Obligations | - |
| Long Term Debt | $4T |
| Current Long Term Debt | $549B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $5.1T |
| Other Current Liabilities | $1.5T |
| Other Non Current Liabilities | $633B |
| Total Shareholder Equity | $6.9T |
| Treasury Stock | - |
| Retained Earnings | $1.2T |
| Common Stock | $1.7T |
| Common Stock Shares Outstanding | $3.2B |
yearly Cash Flow (As of Mar 31, 2025)
| Field | Value (JPY) |
|---|---|
| Operating Cashflow | $1.1T |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $761B |
| Capital Expenditures | $201B |
| Change In Receivables | - |
| Change In Inventory | -$35B |
| Profit Loss | - |
| Cashflow From Investment | -$367B |
| Cashflow From Financing | -$751B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $302B |
| Dividend Payout Common Stock | $302B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$52B |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $108B |
yearly Income Statement (As of Mar 31, 2025)
| Field | Value (JPY) |
|---|---|
| Gross Profit | $3T |
| Total Revenue | $4.6T |
| Cost Of Revenue | $1.6T |
| Costof Goods And Services Sold | $1.6T |
| Operating Income | $343B |
| Selling General And Administrative | $1.1T |
| Research And Development | $730B |
| Operating Expenses | $2.7T |
| Investment Income Net | - |
| Net Interest Income | -$161B |
| Interest Income | $182B |
| Interest Expense | $137B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $761B |
| Income Before Tax | $175B |
| Income Tax Expense | $67B |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $108B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $449B |
| Ebitda | $1.2T |
| Net Income | $108B |
Dividends
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-03-31 |
| Declaration Date | 2025-03-04 |
| Record Date | 2025-03-31 |
| Payment Date | 2025-07-07 |
| Amount | 0.33901 |
TAK News
TAK Profile
Takeda Pharmaceutical Co Ltd ADR Profile
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Discover more tools and features to empower your trading
Explore FeaturesMarket data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.